Southern Arizona Advanced Practice Nurse - Nurse Practitioner Society

Nursing Management of Bone Health in Patients With Cancer

CE Information
1.0 contact hour
Completion Time
1 hour
Available Until
December 18, 2026
Posted By
i3Health
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.

Overview

Specialties
Oncology
Subspecialties
Oncology
Clinical Topics
Bone Cancer and Oncology

STATEMENT OF NEED

Cancer and its treatment often negatively affect bone health. Advanced-stage malignancies frequently metastasize to bone, resulting in pathological fractures, spinal cord compression, pain, disability, reduction in quality of life, and poor prognosis (Hofbauer et al, 2021). In addition to metastasis, certain cancer therapies (eg, hormone therapy and corticosteroids) can have detrimental effects on the skeletal system (Migliorini et al, 2020). Bone-targeted agents may reduce the morbidity of skeletal complications in patients with cancer and significantly improve quality of life (Coleman, Croucher et al, 2020). It is essential that oncology nurses, as key members of the multidisciplinary team, are aware of the adverse effects that cancer and its treatment may have on bone health. It is also crucial that oncology nurses are well-informed regarding interventions to reduce morbidity and mortality. This activity will provide an update on nursing management of bone health in patients with cancer. 

TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the pathophysiology of bone health complications in patients with cancer
  • Distinguish patient- and cancer therapy–related risk factors for bone complication
  • Appraise strategies to manage bone complications in patients with cancer

CE Information

This activity offers 1.0 contact hour to attendees.

Accredited by i3 Health.

Provided by

ACCREDITATION

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development 

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program. OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1 ILNA point toward:

  • Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
  • Oncologic Emergencies (OCN®, CPHON®, AOCNP®)
  • Oncology Nursing Practice (OCN®)
  • Roles of the APRN (AOCNP®)
  • Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
  • Treatment (OCN®, CBCN®, AOCNP®, CPHON®)

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

Disclosures

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of a NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. 

Relevant financial relationships exist between the following individuals and ineligible companies:

  • Steve Bhimji, MD, MSc, PhD, has no relevant financial relationships to disclose
  • Eden E.D. Maack, PhD, has no relevant financial relationships to disclose
  • i3 Health staff members and the peer/content reviewer for this activity have no relevant financial relationships to disclose

i3 Health has mitigated all relevant financial relationships.

UNAPPROVED USE DISCLOSURE

i3 Health requires NCPD faculty to disclose to participants when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty will not discuss information about pharmaceutical agents that is outside of FDA approved labeling. This information is intended solely for educational purposes and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided in this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.


Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Log in and start activity